Clinical Trial Update: Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692) [Phase 3]

View source ↗

Summary

Long-term safety extension results for asenapine in Bipolar I Disorder participants who completed the prior Phase 3 protocol P05691 (P05692). This update pertai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Saphris (asenapine)

Snippet

Sponsor: Forest Laboratories | Conditions: Bipolar I Disorder | Phase 3 | Status: COMPLETED